# EDGAR Filing Document

**Accession Number:** 0001964808
**File Stem:** 0001725160-23-000029
**Filing Date:** 2023-2
**Character Count:** 8877
**Document Hash:** f99074010f0c2f226d18be0494b81c86
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001725160-23-000029.hdr.sgml**: 20230213

**ACCESSION NUMBER**: 0001725160-23-000029

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20230213

**FILED AS OF DATE**: 20230213

**DATE AS OF CHANGE**: 20230213

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Roth Iris
- **CENTRAL INDEX KEY:** 0001964808

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39263
- **FILM NUMBER:** 23614655

**MAIL ADDRESS:**
- **STREET 1:** C/O ZENTALIS PHARMACEUTICALS, INC.
- **STREET 2:** 530 SEVENTH AVENUE, SUITE 2201
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10018
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zentalis Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001725160
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 823607803
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1359 BROADWAY, SUITE 1710
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10018
- **BUSINESS PHONE:** (212) 433-3791

**MAIL ADDRESS:**
- **STREET 1:** 1359 BROADWAY, SUITE 1710
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10018

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Zentalis Pharmaceuticals, LLC
- **DATE OF NAME CHANGE:** 20200107

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Zeno Pharma, LLC
- **DATE OF NAME CHANGE:** 20171212

## Ex-24

![](irispoaedgar001.jpg)

POWER OF ATTORNEY With respect to holdings of and transactions in securities issued by Zentalis Pharmaceuticals, Inc. (the "Company"), the undersigned hereby constitutes and appoints Kimberly Blackwell, Cam Gallagher, Melissa B. Epperly and Andrea Paul, or any of them signing singly, with full power of substitution and resubstitution, to act as the undersigned's true and lawful attorney-in-fact to: 1. execute for and on behalf of the undersigned (a) Schedules 13D and 13G in accordance with Section 13 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder, (b) Forms 3, 4, and 5 in accordance with Section 16 of the Exchange Act and the rules thereunder, and/or (c) Forms 144 in accordance with Rule 144 under the Securities Act of 1933, as amended (the "Securities Act"); 2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Schedule 13D or 13G, Form 3, 4, or 5, or Form 144, complete and execute any amendment or amendments thereto, and timely file such schedule or form with the SEC and any stock exchange or similar authority; and 3. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 13 and Section 16 of the Exchange Act or Rule 144 under the Securities Act. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Schedule 13D and 13G, Forms 3, 4, and 5, and Forms 144 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this __5__ day of February, 2023. Iris Roth DocuSign Envelope ID: EB82C72B-5BE9-4FB3-BDF1-144D1408DD3C

------

![](irispoaedgar002.jpg)

POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that the undersigned (the "Filer"), hereby constitutes and appoints Melissa B. Epperly, Andrea Paul, Karen Pitzi and John Andrews as the Filer's true and lawful attorneys-in-fact and agents and on the Filer's behalf and in the Filer's name, place and stead, in all cases with full power of substitution and resubstitution, in any and all capacities, to submit a Form ID Application and/or Passphrase Update Application and/or Request to Convert from Paper to Electronic Filer, and any amendments thereto, with the U.S. Securities and Exchange Commission ("SEC") and to obtain access codes to file on EDGAR, and grants them full power and authority to do and to perform each and every act and thing requisite and necessary to be done as the Filer might or could do to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC, hereby ratifying and confirming all that said attorneys-in-fact and agents may lawfully do or cause to be done by virtue thereof. IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney on this __5__ day of February, 2023. Iris Roth DocuSign Envelope ID: EB82C72B-5BE9-4FB3-BDF1-144D1408DD3C

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Roth Iris<br><sub>(Last) (First) (Middle)</sub><br>C/O ZENTALIS PHARMACEUTICALS, INC.<br>1359 BROADWAY, SUITE 1710<br><sub>(Street)</sub><br>NEW YORK, NY 10018<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Zentalis Pharmaceuticals, Inc. [ ZNTL ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-02-13 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Operating Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |

---

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** /s/ Andrea Paul, attorney-in-fact for Iris Roth  
**Date:** 2023-02-13

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**